

Open Peer Review on Qeios

Neoantigen-HSP70 Peptide Cancer Vaccine AGEN2017

National Cancer Institute

Source

National Cancer Institute. <u>Neoantigen-HSP70 Peptide Cancer Vaccine AGEN2017</u>. NCI Thesaurus. Code C135018.

A proprietary, personalized autologous synthetic cancer vaccine composed of patient-specific synthetic cancer neo-epitopes complexed with heat shock protein 70 (HSP 70; HSP70), with potential immunostimulating and antineoplastic activities. Upon administration of the neoantigen-HSP70 peptide cancer vaccine AGEN2017, the HSPs present the neoantigens to antigen presenting cells (APCs) and help elicit a potent neoantigen-specific T-cell-based anti-tumor immune response, thereby killing the neoantigen-expressing cancer cells. HSP70 is able to the transport the neo-epitopes, activate APCs and enhance the T-cell-mediated immune response.

Qeios ID: JPJ7MW · https://doi.org/10.32388/JPJ7MW